YTS 106
Alternative Names: YTS-106Latest Information Update: 16 Dec 2022
At a glance
- Originator China Immunotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastrointestinal cancer
Most Recent Events
- 12 Dec 2022 Preclinical trials in Gastrointestinal cancer in China (Parenteral) (China Immunotech pipeline, December 2022)